XML Cancer News

Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC

published about 18 hours ago
(European Society for Medical Oncology) Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody, according to study results presented at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, Spain.

Studies confirm regorafenib benefit in pre-treated metastatic colorectal cancer

published 1 day ago
(European Society for Medical Oncology) The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers announced at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona. The safety profile and progression free survival were similar to phase III trial results.

Scientists advance cancer drug design with image of 1 of key proteins of life

published 2 days ago
(Institute of Cancer Research) Scientists have pioneered the use of a high-powered imaging technique to picture in exquisite detail one of the central proteins of life -- a cellular recycling unit with a role in many diseases.

Experts call for 'all hands on deck' to tackle global burden of non-communicable disease

published 2 days ago
(European Society of Cardiology) A group of the world's top doctors and scientists working in cardiology and preventive medicine have issued a call to action to tackle the global problem of deaths from non-communicable diseases, such as heart problems, diabetes and cancer, through healthy lifestyle initiatives. Their suggestions to prevent or delay health conditions that cause the deaths of over 36 million people worldwide each year are published simultaneously in Mayo Clinic Proceedings and the European Heart Journal.

Launch of first European nanomedicine characterization lab

published 2 days ago
(Swiss Federal Laboratories for Materials Science and Technology (EMPA)) Empa, the Swiss Federal Laboratories for Materials Science and Technology, is part of the collaborative 'European Nanomedicine Characterization Laboratory,' a European project funded by the EU framework program 'Horizon 2020.' Its goal is to reach a level of international excellence in nanomedicine characterization for diseases like cancer, diabetes, inflammatory diseases or infections. This competence will be made accessible to all organizations developing candidate nanomedicines prior to their submission to regulatory agencies ... more